A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Public ClinicalTrials.gov record NCT06628310. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)
Study identification
- NCT ID
- NCT06628310
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
- Budigalimab Drug
- Fluorouracil Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Telisotuzumab Adizutecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2024
- Primary completion
- Sep 30, 2030
- Completion
- Sep 30, 2030
- Last update posted
- Mar 29, 2026
2024 – 2030
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center /ID# 268690 | Duarte | California | 91010 | Recruiting |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 272630 | Irvine | California | 92618 | Recruiting |
| UCLA - Santa Monica /ID# 270024 | Santa Monica | California | 90404 | Recruiting |
| AdventHealth Orlando /ID# 268561 | Orlando | Florida | 32803 | Recruiting |
| City Of Hope - Atlanta. /ID# 280646 | Newnan | Georgia | 30265 | Recruiting |
| Hattiesburg Clinic /ID# 268572 | Hattiesburg | Mississippi | 39401 | Recruiting |
| Duke University Medical Center /ID# 268186 | Durham | North Carolina | 27710 | Recruiting |
| Millennium Research & Clinical Development /ID# 268540 | Houston | Texas | 77090 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06628310, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06628310 live on ClinicalTrials.gov.